Irritable bowel syndrome and inflammatory bowel disease differ in their natural evolution, etiopathogenesis, diagnostic criteria, and therapeutic approach. However, recent evidence has suggested some similarities in mechanisms underlying symptom development and progression. There is a relevant role for alterations in the microbiome-brain-gut axis in both diseases. The presence of irritable bowel syndrome symptoms in patients with quiescent inflammatory bowel disease is common in clinical practice. To determine the cause of irritable bowel syndrome symptoms in patients with quiescent inflammatory bowel disease is a clinical challenge. This review aims to illustrate possible causes and solutions for these patients.
|Number of pages||23|
|Journal||Gastroenterology Clinics of North America|
|State||Published - 1 Sep 2021|
Bibliographical noteFunding Information:
Conflicts of Interest: Drs E. Pérez de Arce and R. Quera report no conflicts. Dr E.M.M. Quigley serves as a consultant to 4D Pharma, Allergan, Atlantia, Biocodex, Ironwood, Novozymes, Precisionbiotics, Salix, and Vibrant and receives research funding from 4D Pharma , Biomerica , Vibrant , and Zealand Pharma .
- Brain–gut axis
- Crohn's disease
- Fecal calprotectin
- Inflammatory bowel disease
- Irritable bowel syndrome
- Ulcerative colitis